Clinical and Experimental Nephrology

, Volume 22, Issue 1, pp 133–141 | Cite as

Urinary biomarkers in the early detection and follow-up of tubular injury in childhood urolithiasis

  • Mehmet TaşdemirEmail author
  • Dilara Fuçucuoğlu
  • Suat Hayri Küçük
  • Meltem Erol
  • Özgül Yiğit
  • Ilmay Bilge
Original article



To investigate relationships among urinary biomarkers [kidney injury molecule-1 (KIM-1), N-acetyl-β-glucosaminidase (NAG)], neutrophil gelatinase-associated lipocalin (NGAL) levels and renal tubular injury in childhood urolithiasis.


Seventy children [36 girls, mean age: 7.3 ± 5.0 years (0.5–18.2)] with urolithiasis/microlithiasis and 42 controls [18 girls, mean age: 8.5 ± 3.8 years (0.9–16.2)] were included in this multicenter, controlled, prospective cohort study. Patients were evaluated three times in 6-month intervals (0, 6 and 12th months). Anthropometric data, urinary symptoms, family history and diagnostic studies were recorded. Urine samples were analyzed for metabolic risk factors (urinary calcium, uric acid, oxalate, citrate, cystine, magnesium, and creatinine excretion), and the urinary KIM-1, NAG, and NGAL levels were measured.


Stones were mostly located in the upper urinary system (82.9%), and six patients (8.6%) had hydronephrosis. Thirty patients (42.9%) had several metabolic risk factors, and the most common metabolic risk factor was hypocitraturia (22.9%). Urinary KIM-1/Cr, NAG/Cr and NGAL/Cr ratios were not significantly different between patients and controls. Furthermore, no significant changes in their excretion were shown during follow-up. Notably, the urinary KIM-1/Cr, NAG/Cr, and NGAL/Cr levels were significantly higher in children under 2 years of age (p = 0.011, p = 0.006, and 0.015, respectively). NAG/Cr and NGAL/Cr ratios were significantly increased in patients with hydronephrosis (n = 6, p = 0.031 and 0.023, respectively).


The results of this study suggest that none of the aforementioned urinary biomarkers (KIM-1, NAG and NGAL levels) may be useful for the early detection and/or follow-up of renal tubular injury and/or dysfunction in childhood urolithiasis.


Kidney stone disease Biomarkers Metabolic abnormalities Kidney injury molecule-1 N-acetyl-β-glucosaminidase Neutrophil gelatinase-associated lipocalin 



We thank the patients and their families taking part in this study. Proofreading was performed by American Journal Experts (Certificate Verification Key: 9A3B-B552-136B-C6A6-7B52).

Compliance with ethical standards

Conflict of interest

The authors have declared that no conflict of interest exists.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (Ministry of Health Bağcılar Training and Research Hospital, date 22/04/2014, and no: 04) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Pearle MS, Antonelli JA, Lotan Y. Urinary lithiasis: etiology, epidemology, and pathogenesis. In: Wein AJ, editor. Campbell–Walsh urology. 17th ed. Philadelphia: Elsevier; 2016. p. 1170–99.Google Scholar
  2. 2.
    Edvardsson V, Elidottir H, Indridason OS, Palsson R. High incidence of kidney stones in Icelandic children. Pediatr Nephrol. 2005;20(7):940–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Sas DJ, Hulsey TC, Shatat IF, Orak JK. Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr. 2010;157(1):132–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Celiksoy MH, Yilmaz A, Aydogan G, Kiyak A, Topal E, Sander S. Metabolic disorders in Turkish children with urolithiasis. Urology. 2015;85(4):909–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Elmaci AM, Ece A, Akin F. Clinical characteristics and metabolic abnormalities in preschool-age children with urolithiasis in southeast Anatolia. J Pediatr Urol. 2014;10(3):495–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Bastug F, Dusunsel R. Pediatric urolithiasis: causative factors, diagnosis and medical management. Nat Rev Urol. 2012;9(3):138–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Alpay H, Ozen A, Gokce I, Biyikli N. Clinical and metabolic features of urolithiasis and microlithiasis in children. Pediatr Nephrol. 2009;24(11):2203–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Bilge I, Yilmaz A, Kayiran SM, Emre S, Kadioglu A, Yekeler E, et al. Clinical importance of renal calyceal microlithiasis in children. Pediatr Int. 2013;55(6):731–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Lieske JC, Toback FG. Renal cell-urinary crystal interactions. Curr Opin Nephrol Hypertens. 2000;9(4):349–55.CrossRefPubMedGoogle Scholar
  10. 10.
    Balasar M, Piskin MM, Topcu C, Demir LS, Gurbilek M, Kandemir A, et al. Urinary kidney injury molecule-1 levels in renal stone patients. World J Urol. 2016;. doi: 10.1007/s00345-016-1765-y.PubMedGoogle Scholar
  11. 11.
    Daggulli M, Utangac MM, Dede O, Bodakci MN, Hatipoglu NK, Penbegul N, et al. Potential biomarkers for the early detection of acute kidney injury after percutaneous nephrolithotripsy. Ren Fail. 2016;38(1):151–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol. 2004;286(3):F552–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Kuehn EW, Park KM, Somlo S, Bonventre JV. Kidney injury molecule-1 expression in murine polycystic kidney disease. Am J Physiol Renal Physiol. 2002;283(6):F1326–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, et al. Urinary N-acetyl-beta-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18(3):904–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Nepal M, Bock GH, Sehic AM, Schultz MF, Zhang PL. Kidney injury molecule-1 expression identifies proximal tubular injury in urate nephropathy. Ann Clin Lab Sci. 2008;38(3):210–4.PubMedGoogle Scholar
  17. 17.
    Sikora P, Glatz S, Beck BB, Stapenhorst L, Zajaczkowska M, Hesse A, et al. Urinary NAG in children with urolithiasis, nephrocalcinosis, or risk of urolithiasis. Pediatr Nephrol. 2003;18(10):996–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Winter P, Ganter K, Heimbach D, Hesse A. N-acetyl-beta-d-glucosaminidase excretion in calcium oxalate stone patients and its relation to the risk of stone formation. Scand J Urol Nephrol. 1996;30(6):439–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Yilmaz A, Sevketoglu E, Gedikbasi A, Karyagar S, Kiyak A, Mulazimoglu M, et al. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr Nephrol. 2009;24(12):2387–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhu W, Liu M, Wang GC, Che JP, Xu YF, Peng B, et al. Urinary neutrophil gelatinase-associated lipocalin, a biomarker for systemic inflammatory response syndrome in patients with nephrolithiasis. J Surg Res. 2014;187(1):237–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Jobs K, Straz-Zebrowska E, Placzynska M, Zdanowski R, Kalicki B, Lewicki S, et al. Interleukin-18 and NGAL in assessment of ESWL treatment safety in children with urolithiasis. Cent Eur J Immunol. 2014;39(3):384–91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hoppe B, Leuman E, Milliner DS. Urolithiasis and nephrocalcinosis in childhood. In: Geary DF, editor. Comprehensive pediatric nephrology. 1st ed. Philadelphia: Mosby; 2008. p. 499–526.CrossRefGoogle Scholar
  23. 23.
    Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 2006;290(2):F517–29.CrossRefPubMedGoogle Scholar
  24. 24.
    Dance N, Price RG, Robinson D, Stirling JL. Beta-galactosidase, beta-glucosidase and N-acetyl-beta-glucosaminidase in human kidney. Clin Chim Acta. 1969;24(2):189–97.CrossRefPubMedGoogle Scholar
  25. 25.
    Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 2010;36(3):452–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Kardakos IS, Volanis DI, Kalikaki A, Tzortzis VP, Serafetinides EN, Melekos MD, et al. Evaluation of neutrophil gelatinase-associated lipocalin, interleukin-18, and cystatin C as molecular markers before and after unilateral shock wave lithotripsy. Urology. 2014;84(4):783–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP. Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr. 1997;131(2):252–7.CrossRefPubMedGoogle Scholar
  28. 28.
  29. 29.
    Walther PC, Lamm D, Kaplan GW. Pediatric urolithiases: a ten-year review. Pediatrics. 1980;65(6):1068–72.PubMedGoogle Scholar
  30. 30.
    Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc. 1993;68(3):241–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Dursun I, Poyrazoglu HM, Dusunsel R, Gunduz Z, Gurgoze MK, Demirci D, et al. Pediatric urolithiasis: an 8-year experience of single centre. Int Urol Nephrol. 2008;40(1):3–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Coward RJ, Peters CJ, Duffy PG, Corry D, Kellett MJ, Choong S, et al. Epidemiology of paediatric renal stone disease in the UK. Arch Dis Child. 2003;88(11):962–5.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Tefekli A, Esen T, Ziylan O, Erol B, Armagan A, Ander H, et al. Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference? Urol Int. 2003;70(4):273–7.CrossRefPubMedGoogle Scholar
  34. 34.
    VanDervoort K, Wiesen J, Frank R, Vento S, Crosby V, Chandra M, et al. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol. 2007;177(6):2300–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab. 1990;71(4):861–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Hess B, Michel R, Takkinen R, Ackermann D, Jaeger P. Risk factors for low urinary citrate in calcium nephrolithiasis: low vegetable fibre intake and low urine volume to be added to the list. Nephrol Dial Transplant. 1994;9(6):642–9.CrossRefPubMedGoogle Scholar
  37. 37.
    McKay CP. Renal stone disease. Pediatr Rev. 2010;31(5):179–88.CrossRefPubMedGoogle Scholar
  38. 38.
    Waanders F, van Timmeren MM, Stegeman CA, Bakker SJ, van Goor H. Kidney injury molecule-1 in renal disease. J Pathol. 2010;220(1):7–16.CrossRefPubMedGoogle Scholar
  39. 39.
    Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135–42.CrossRefPubMedGoogle Scholar
  40. 40.
    van Timmeren MM, Bakker SJ, Vaidya VS, Bailly V, Schuurs TA, Damman J, et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol. 2006;291(2):F456–64.CrossRefPubMedGoogle Scholar
  41. 41.
    van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007;212(2):209–17.CrossRefPubMedGoogle Scholar
  42. 42.
    Kandur Y, Gonen S, Fidan K, Soylemezoglu O. Evaluation of urinary KIM-1, NGAL, and IL-18 levels in determining early renal injury in pediatric cases with hypercalciuria and/or renal calculi. Clin Nephrol. 2016;86(2):62–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Baggio B, Gambaro G, Ossi E, Favaro S, Borsatti A. Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis. J Urol. 1983;129(6):1161–2.CrossRefPubMedGoogle Scholar
  44. 44.
    Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534–43.CrossRefPubMedGoogle Scholar
  45. 45.
    Vanpee M, Blennow M, Linne T, Herin P, Aperia A. Renal function in very low birth weight infants: normal maturity reached during early childhood. J Pediatr. 1992;121(5):784–8.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2017

Authors and Affiliations

  1. 1.Division of Pediatric Nephrology, Department of PediatricsKoç University HospitalIstanbulTurkey
  2. 2.Department of Pediatrics, Ministry of HealthBağcılar Training and Research HospitalIstanbulTurkey
  3. 3.Department of Biochemistry, Ministry of HealthBağcılar Training and Research HospitalIstanbulTurkey
  4. 4.Division of Pediatric Nephrology, Department of Pediatrics, School of MedicineKoc UniversityIstanbulTurkey

Personalised recommendations